Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies

The Lancet Diabetes and Endocrinology

Volumn 7, Issue 4, 2019, Pages 313-324

  Stefan, Norbert ^a,b,c   Häring, Hans Ulrich ^a,b,c   Cusi, Kenneth ^d,e  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c GERMAN CENTER FOR DIABETES RESEARCH DZD   (Germany)

^d UNIVERSITY OF FLORIDA   (United States)

^e Malcom Randal Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFIBROTIC AGENT; ADIPONUTRIN, HUMAN; ANTIOXIDANT; INCRETIN; MEMBRANE PROTEIN; TM6SF2 PROTEIN, HUMAN; TRIACYLGLYCEROL LIPASE;

ALLELE; BODY WEIGHT LOSS; CARDIOMETABOLIC RISK; CARDIOVASCULAR DISEASE; COMORBIDITY; DISEASE EXACERBATION; FAT MASS; GENETIC RISK; HUMAN; INSULIN RESISTANCE; LIFESTYLE; LIVER CIRRHOSIS; LIVER PROTECTION; METABOLIC DISORDER; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NON INVASIVE MEASUREMENT; NONALCOHOLIC FATTY LIVER; PREDICTION; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; STAGING; ABDOMINAL OBESITY; BARIATRIC SURGERY; DRUG THERAPY; DYSBIOSIS; GENETIC PREDISPOSITION; GENETICS; INTESTINE FLORA; LIVER CELL CARCINOMA; LIVER TUMOR; METABOLISM; RISK REDUCTION;

ANTIOXIDANTS; BARIATRIC SURGERY; CARCINOMA, HEPATOCELLULAR; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; DYSBIOSIS; GASTROINTESTINAL MICROBIOME; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INCRETINS; INSULIN RESISTANCE; LIPASE; LIVER CIRRHOSIS; LIVER NEOPLASMS; MEMBRANE PROTEINS; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY, ABDOMINAL; RISK ASSESSMENT; RISK REDUCTION BEHAVIOR; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS;

EID: 85062480923     PISSN: 22138587     EISSN: 22138595     Source Type: Journal    
DOI: 10.1016/S2213-8587(18)30154-2     Document Type: Review

References (125)

1. Younossi, ZM, Koenig, AB, Abdelatif, D, Fazel, Y, Henry, L, Wymer, M, Global epidemiology of nonalcoholic fatty liver disease—meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64 (2016), 73–84.
2. Anderson, EL, Howe, LD, Jones, HE, Higgins, JPT, Lawlor, DA, Fraser, A, The prevalence of non-alcoholic fatty liver disease in children and adolescents: a systematic review and meta-analysis. PLoS One, 10, 2015, e0140908.
3. Alisi, A, Feldstein, AE, Villani, A, Raponi, M, Nobili, V, Pediatric nonalcoholic fatty liver disease: a multidisciplinary approach. Nat Rev Gastroenterol Hepatol 9 (2012), 152–161.
4. GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 390 (2017), 1211–1259.
5. GBD 2016 Risk Factors Collaborators. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 390 (2017), 1345–1422.
6. Pearson-Stuttard, J, Zhou, B, Kontis, V, Bentham, J, Gunter, MJ, Ezzati, M, Worldwide burden of cancer attributable to diabetes and high body-mass index: a comparative risk assessment. Lancet Diabetes Endocrinol 6 (2018), e6–e15.
7. Younossi, ZM, Otgonsuren, M, Henry, L, et al. Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009. Hepatology 62 (2015), 1723–1730.
8. Micha, R, Peñalvo, JL, Cudhea, F, Imamura, F, Rehm, CD, Mozaffarian, D, Association between dietary factors and mortality from heart disease, stroke, and type 2 diabetes in the United States. JAMA 317 (2017), 912–924.
9. Khera, AV, Emdin, CA, Drake, I, et al. Genetic risk, adherence to a healthy lifestyle, and coronary disease. N Engl J Med 375 (2016), 2349–2358.
10. Stefan, N, Häring, HU, Hu, FB, Schulze, MB, Divergent associations of height with cardiometabolic disease and cancer: epidemiology, pathophysiology, and global implications. Lancet Diabetes Endocrinol 4 (2016), 457–467.
11. Eslamparast, T, Tandon, P, Raman, M, Dietary composition independent of weight loss in the management of non-alcoholic fatty liver disease. Nutrients, 9, 2017, 800.
12. Ekstedt, M, Hagström, H, Nasr, P, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 61 (2015), 1547–1554.
13. Angulo, P, Kleiner, DE, Dam-Larsen, S, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 149 (2015), 389–397.
14. Yki-Järvinen, H, Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. Lancet Diabetes Endocrinol 2 (2014), 901–910.
15. Stefan, N, Fritsche, A, Schick, F, Häring, HU, Phenotypes of prediabetes and stratification of cardiometabolic risk. Lancet Diabetes Endocrinol 4 (2016), 789–798.
16. Stefan, N, Schick, F, Häring, HU, Causes, characteristics, and consequences of metabolically unhealthy normal weight in humans. Cell Metab 26 (2017), 292–300.
17. Bril, F, Cusi, K, Management of nonalcoholic fatty liver disease in patients with type 2 diabetes: a call to action. Diabetes Care 40 (2017), 419–430.
18. Bril, F, Barb, D, Portillo-Sanchez, P, et al. Metabolic and histological implications of intrahepatic triglyceride content in nonalcoholic fatty liver disease. Hepatology 65 (2017), 1132–1144.
19. Gastaldelli, A, Insulin resistance and reduced metabolic flexibility: cause or consequence of NAFLD?. Clin Sci (Lond) 131 (2017), 2701–2704.
20. Byrne, CD, Targher, G, NAFLD: a multisystem disease. J Hepatol 62 (2015), S47–S64.
21. Younossi, Z, Anstee, QM, Marietti, M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol 15 (2018), 11–20.
22. Rinella, ME, Nonalcoholic fatty liver disease: a systematic review. JAMA 313 (2015), 2263–2273.
23. Stefan, N, Häring, HU, Schulze, MB, Metabolically healthy obesity: the low-hanging fruit in obesity treatment?. Lancet Diabetes Endocrinol 6 (2018), 249–258.
24. Donnelly, KL, Smith, CI, Schwarzenberg, SJ, Jessurun, J, Boldt, MD, Parks, EJ, Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 115 (2005), 1343–1351.
25. Stefan, N, Kantartzis, K, Häring, HU, Causes and metabolic consequences of fatty liver. Endocr Rev 29 (2008), 939–960.
26. Petersen, MC, Shulman, GI, Roles of diacylglycerols and ceramides in hepatic insulin resistance. Trends Pharmacol Sci 38 (2017), 649–665.
27. Marra, F, Svegliati-Baroni, G, Lipotoxicity and the gut-liver axis in NASH pathogenesis. J Hepatol 68 (2018), 280–295.
28. Bacchi, E, Negri, C, Targher, G, et al. Both resistance training and aerobic training reduce hepatic fat content in type 2 diabetic subjects with nonalcoholic fatty liver disease (the RAED2 randomized trial). Hepatology 58 (2013), 1287–1295.
29. Lomonaco, R, Sunny, NE, Bril, F, Cusi, K, Nonalcoholic fatty liver disease: current issues and novel treatment approaches. Drugs 73 (2013), 1–14.
30. Kennedy, BK, Berger, SL, Brunet, A, et al. Geroscience: linking aging to chronic disease. Cell 159 (2014), 709–713.
31. Kalinkovich, A, Livshits, G, Sarcopenic obesity or obese sarcopenia: a cross talk between age-associated adipose tissue and skeletal muscle inflammation as a main mechanism of the pathogenesis. Ageing Res Rev 35 (2017), 200–221.
32. Tchkonia, T, Thomou, T, Zhu, Y, et al. Mechanisms and metabolic implications of regional differences among fat depots. Cell Metab 17 (2013), 644–656.
33. Palmer, BF, Clegg, DJ, The sexual dimorphism of obesity. Mol Cell Endocrinol 402 (2015), 113–119.
34. Eslam, M, Valenti, L, Romeo, S, Genetics and epigenetics of NAFLD and NASH: clinical impact. J Hepatol 68 (2018), 268–279.
35. Anstee, QM, Seth, D, Day, CP, Genetic factors that affect risk of alcoholic and nonalcoholic fatty liver disease. Gastroenterology 150 (2016), 1728–1744.
36. Abul-Husn, NS, Cheng, X, Li, AH, et al. A protein-truncating HSD17B13 variant and protection from chronic liver disease. N Engl J Med 378 (2018), 1096–1106.
37. Hernaez, R, Lazo, M, Bonekamp, S, et al. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis. Hepatology 54 (2011), 1082–1090.
38. Szczepaniak, LS, Nurenberg, P, Leonard, D, et al. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab 288 (2005), E462–E468.
39. Bril, F, Ortiz-Lopez, C, Lomonaco, R, et al. Clinical value of liver ultrasound for the diagnosis of nonalcoholic fatty liver disease in overweight and obese patients. Liver Int 35 (2015), 2139–2146.
40. Bedogni, G, Bellentani, S, Miglioli, L, et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gatroenterol, 6, 2006, 33.
41. Kantartzis, K, Rettig, I, Staiger, H, et al. An extended fatty liver index to predict non-alcoholic fatty liver disease. Diabetes Metab 43 (2017), 229–239.
42. Lee, SS, Park, SH, Kim, HJ, et al. Non-invasive assessment of hepatic steatosis: prospective comparison of the accuracy of imaging examinations. J Hepatol 52 (2010), 579–585.
43. Karlas, T, Petroff, D, Sasso, M, et al. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. J Hepatol 66 (2017), 1022–1030.
44. Park, CC, Nguyen, P, Hernandez, C, et al. Magnetic resonance elastography vs transient elastography in detection of fibrosis and noninvasive measurement of steatosis in patients with biopsy-proven nonalcoholic fatty liver disease. Gastroenterology 152 (2017), 598–607.
45. Younossi, ZM, Loomba, R, Anstee, QM, et al. Diagnostic modalities for non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH) and associated fibrosis. Hepatology, 2017 published online Dec 9. DOI:10.1002/hep.29721.
46. Verma, S, Jensen, D, Hart, J, Mohanty, SR, Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD). Liver Int 33 (2013), 1398–1405.
47. Tapper, EB, Lok, AS, Use of liver imaging and biopsy in clinical practice. N Engl J Med 377 (2017), 756–768.
48. Castera, L, Noninvasive assessment of liver fibrosis. Dig Dis 33 (2015), 498–503.
49. Cusi, K, Chang, Z, Harrison, S, et al. Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver disease. J Hepatol 60 (2014), 167–174.
50. Angulo, P, Hui, JM, Marchesini, G, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 45 (2007), 846–854.
51. Shah, AG, Lydecker, A, Murray, K, et al. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 7 (2009), 1104–1112.
52. European Association for the Study of the Liver (EASL) European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. Diabetologia 59 (2016), 1121–1140.
53. Chalasani, N, Younossi, Z, Lavine, JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology 67 (2018), 328–357.
54. Rosenberg, WM, Voelker, M, Thiel, R, et al. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology 127 (2004), 1704–1713.
55. Ratziu, V, Massard, J, Charlotte, F, et al. Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol, 6, 2006, 6.
56. Afdhal, NH, Bacon, BR, Patel, K, et al. Accuracy of fibroscan, compared with histology, in analysis of liver fibrosis in patients with hepatitis B or C: a United States multicenter study. Clin Gastroenterol Hepatol 13 (2015), 772–779.
57. Loomba, R, Role of imaging-based biomarkers in NAFLD: recent advances in clinical application and future research directions. J Hepatol 68 (2018), 296–304.
58. Banerjee, R, Pavlides, M, Tunnicliffe, EM, et al. Multiparametric magnetic resonance for the non-invasive diagnosis of liver disease. J Hepatol 60 (2014), 69–77.
59. Singh, S, Allen, AM, Wang, Z, Prokop, LJ, Murad, MH, Loomba, R, Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol 13 (2015), 643–654.
60. McPherson, S, Hardy, T, Henderson, E, Burt, AD, Day, CP, Anstee, QM, Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. J Hepatol 62 (2015), 1148–1155.
61. Bril, F, Cusi, K, Nonalcoholic fatty liver disease: the new complication of type 2 diabetes mellitus. Endocrinol Metab Clin North Am 45 (2016), 765–781.
62. Samuel, VT, Shulman, GI, Nonalcoholic fatty liver disease as a nexus of metabolic and hepatic diseases. Cell Metab 27 (2018), 22–41.
63. Santhekadur, PK, Kumar, DP, Sanyal, AJ, Preclinical models of non-alcoholic fatty liver disease. J Hepatol 68 (2018), 230–237.
64. Adams, LA, Anstee, QM, Tilg, H, Targher, G, Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut 66 (2017), 1138–1153.
65. Pisto, P, Santaniemi, M, Bloigu, R, Ukkola, O, Kesäniemi, YA, Fatty liver predicts the risk for cardiovascular events in middle-aged population: a population-based cohort study. BMJ Open, 4, 2014, e004973.
66. Saltiel, AR, Kahn, CR, Insulin signalling and the regulation of glucose and lipid metabolism. Nature 414 (2001), 799–806.
67. Stefan, N, Häring, HU, The role of hepatokines in metabolism. Nat Rev Endocrinol 9 (2013), 144–152.
68. Dulai, PS, Singh, S, Patel, J, et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis. Hepatology 65 (2017), 1557–1565.
69. Hagström, H, Nasr, P, Ekstedt, M, et al. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. J Hepatol 67 (2017), 1265–1273.
70. Tilg, H, Moschen, AR, Roden, M, NAFLD and diabetes mellitus. Nat Rev Gastroenterol Hepatol 14 (2017), 32–42.
71. Stefan, N, Kantartzis, K, Machann, J, et al. Identification and characterization of metabolically benign obesity in humans. Arch Intern Med 168 (2008), 1609–1616.
72. Kantartzis, K, Machann, J, Schick, F, Fritsche, A, Häring, HU, Stefan, N, The impact of liver fat vs visceral fat in determining categories of prediabetes. Diabetologia 53 (2010), 882–889.
73. Fabbrini, E, Magkos, F, Mohammed, BS, et al. Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity. Proc Natl Acad Sci USA 106 (2009), 15430–15435.
74. Fabbrini, E, Yoshino, J, Yoshino, M, et al. Metabolically normal obese people are protected from adverse effects following weight gain. J Clin Invest 125 (2015), 787–795.
75. Lauridsen, BK, Stender, S, Kristensen, TS, et al. Liver fat content, non-alcoholic fatty liver disease, and ischaemic heart disease: mendelian randomization and meta-analysis of 279 013 individuals. Eur Heart J 39 (2018), 385–393.
76. Liu, DJ, Peloso, GM, Yu, H, et al. Exome-wide association study of plasma lipids in >300,000 individuals. Nat Genet 49 (2017), 1758–1766.
77. BasuRay, S, Smagris, E, Cohen, JC, Hobbs, HH, The PNPLA3 variant associated with fatty liver disease (I148M) accumulates on lipid droplets by evading ubiquitylation. Hepatology 66 (2017), 1111–1124.
78. Kollerits, B, Coassin, S, Beckmann, ND, et al. Genetic evidence for a role of adiponutrin in the metabolism of apolipoprotein B-containing lipoproteins. Hum Mol Genet 18 (2009), 4669–4676.
79. Fan, Y, Lu, H, Guo, Y, et al. Hepatic transmembrane 6 superfamily member 2 regulates cholesterol metabolism in mice. Gastroenterology 150 (2016), 1208–1218.
80. Musso, G, Cipolla, U, Cassader, M, et al. TM6SF2 rs58542926 variant affects postprandial lipoprotein metabolism and glucose homeostasis in NAFLD. J Lipid Res 58 (2017), 1221–1229.
81. Jo, H, Choe, SS, Shin, KC, et al. Endoplasmic reticulum stress induces hepatic steatosis via increased expression of the hepatic very low-density lipoprotein receptor. Hepatology 57 (2013), 1366–1377.
82. Männistö VT, Simonen, M, Soininen, P, et al. Lipoprotein subclass metabolism in nonalcoholic steatohepatitis. J Lipid Res 55 (2014), 2676–2684.
83. Lotta, LA, Sharp, SJ, Burgess, S, et al. Association between low-density lipoprotein cholesterol lowering genetic variants and risk of type 2 diabetes: a meta-analysis. JAMA 316 (2016), 1383–1391.
84. Stender, S, Kozlitina, J, Nordestgaard, BG, Tybjærg-Hansen, A, Hobbs, HH, Cohen, JC, Adiposity amplifies the genetic risk of fatty liver disease conferred by multiple loci. Nat Genet 49 (2017), 842–847.
85. Neuschwander-Tetri, BA, Loomba, R, Sanyal, AJ, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 385 (2015), 956–965.
86. Ratziu, V, Harrison, S, Francque, SM, et al. Elafibranor, an agonist of the peroxisome proliferator-activated receptor-α and -δ induces resolution of nonalcoholic steatohepatitis without fibrosis worsening. Gastroenterology 150 (2016), 1147–1159.
87. Friedman, SL, Ratziu, V, Harrison, SA, et al. A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis. Hepatology 67 (2018), 1754–1767.
88. Ratziu, V, A critical review of endpoints for non-cirrhotic NASH therapeutic trials. J Hepatol 68 (2018), 353–361.
89. Cusi, K, Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions. Diabetologia 59 (2016), 1112–1120.
90. Younossi, ZM, Loomba, R, Rinella, ME, et al. Current and future therapeutic regimens for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Hepatology, 2017 published online Dec 9. DOI:10.1002/hep.29724.
91. Townsend, SA, Newsome, PN, Review article: new treatments in non-alcoholic fatty liver disease. Aliment Pharmacol Ther 46 (2017), 494–507.
92. Diehl, AM, Day, C, Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis. N Engl J Med 377 (2017), 2063–2072.
93. Cusi, K, Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications. Gastroenterology 142 (2012), 711–725.
94. Rowe, IA, Too much medicine: overdiagnosis and overtreatment of non-alcoholic fatty liver disease. Lancet Gastroenterol Hepatol 3 (2018), 66–72.
95. Marchesini, G, Petta, S, Dalle Grave, R, Diet, weight loss, and liver health in nonalcoholic fatty liver disease: pathophysiology, evidence, and practice. Hepatology 63 (2016), 2032–2043.
96. Barb, D, Portillo-Sanchez, P, Cusi, K, Pharmacological management of nonalcoholic fatty liver disease. Metabolism 65 (2016), 1183–1195.
97. Promrat, K, Kleiner, DE, Niemeier, HM, et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 51 (2010), 121–129.
98. Vilar-Gomez, E, Martinez-Perez, Y, Calzadilla-Bertot, L, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology 149 (2015), 367–378.
99. Goossens, N, Hoshida, Y, Song, WM, et al. Nonalcoholic steatohepatitis is associated with increased mortality in obese patients undergoing bariatric surgery. Clin Gastroenterol Hepatol 14 (2016), 1619–1628.
100. Belfort, R, Harrison, SA, Brown, K, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 355 (2006), 2297–2307.
101. Cusi, K, Orsak, B, Bril, F, et al. Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial. Ann Intern Med 165 (2016), 305–315.
102. Aithal, GP, Thomas, JA, Kaye, PV, et al. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology 135 (2008), 1176–1184.
103. Sanyal, AJ, Chalasani, N, Kowdley, KV, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 362 (2010), 1675–1685.
104. Bril, F, Kalavalapalli, S, Clark, VC, et al. Response to pioglitazone in patients with nonalcoholic steatohepatitis with vs without type 2 diabetes. Clin Gastroenterol Hepatol 16 (2018), 558–566.
105. Musso, G, Cassader, M, Paschetta, E, Gambino, R, Thiazolidinediones and advanced liver fibrosis in nonalcoholic steatohepatitis: a meta-analysis. JAMA Intern Med 177 (2017), 633–640.
106. DeFronzo, RA, Tripathy, D, Schwenke, DC, et al. Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med 364 (2011), 1104–1115.
107. Kernan, WN, Viscoli, CM, Furie, KL, et al. Pioglitazone after ischemic stroke or transient ischemic attack. N Engl J Med 374 (2016), 1321–1331.
108. Yau, H, Rivera, K, Lomonaco, R, Cusi, K, The future of thiazolidinedione therapy in the management of type 2 diabetes mellitus. Curr Diab Rep 13 (2013), 329–341.
109. Bril, F, Sninsky, JJ, Baca, AM, et al. Hepatic steatosis and insulin resistance, but not steatohepatitis, promote atherogenic dyslipidemia in NAFLD. J Clin Endocrinol Metab 101 (2016), 644–652.
110. Lincoff, AM, Wolski, K, Nicholls, SJ, Nissen, SE, Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 298 (2007), 1180–1188.
111. Mazzone, T, Meyer, PM, Feinstein, SB, et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA 296 (2006), 2572–2581.
112. Nissen, SE, Nicholls, SJ, Wolski, K, et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 299 (2008), 1561–1573.
113. Dormandy, JA, Charbonnel, B, Eckland, DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366 (2005), 1279–1289.
114. Zghebi, SS, Steinke, DT, Rutter, MK, Emsley, RA, Ashcroft, DM, Comparative risk of major cardiovascular events associated with second-line antidiabetic treatments: a retrospective cohort study using UK primary care data linked to hospitalization and mortality records. Diabetes Obes Metab 18 (2016), 916–924.
115. Strongman, H, Christopher, S, Majak, M, et al. Pioglitazone and cause-specific risk of mortality in patients with type 2 diabetes: extended analysis from a European multidatabase cohort study. BMJ Open Diabetes Res Care, 6, 2018, e000481.
116. Vaccaro, O, Masulli, M, Nicolucci, A, et al. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. Lancet Diabetes Endocrinol 5 (2017), 887–897.
117. Balas, B, Belfort, R, Harrison, SA, et al. Pioglitazone treatment increases whole body fat but not total body water in patients with non-alcoholic steatohepatitis. J Hepatol 47 (2007), 565–570.
118. Viscoli, CM, Inzucchi, SE, Young, LH, et al. Pioglitazone and risk for bone fracture: safety data from a randomized clinical trial. J Clin Endocrinol Metab 102 (2017), 914–922.
119. Clarke, GD, Solis-Herrera, C, Molina-Wilkins, M, et al. Pioglitazone improves left ventricular diastolic function in subjects with diabetes. Diabetes Care 40 (2017), 1530–1536.
120. Lewis, JD, Habel, LA, Quesenberry, CP, et al. Pioglitazone use and risk of bladder cancer and other common cancers in persons with diabetes. JAMA 314 (2015), 265–277.
121. Davidson, MB, Pan, D, An updated meta-analysis of pioglitazone exposure and bladder cancer and comparison to the drug's effect on cardiovascular disease and non-alcoholic steatohepatitis. Diabetes Res Clin Pract 135 (2018), 102–110.
122. Armstrong, MJ, Gaunt, P, Aithal, GP, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo controlled phase 2 study. Lancet 387 (2016), 679–690.
123. Dhir, G, Cusi, K, Glucagon like peptide-1 receptor agonists for the management of obesity and non-alcoholic fatty liver disease: a novel therapeutic option. J Investig Med 66 (2018), 7–10.
124. Cefalu, WT, Kaul, S, Gerstein, HC, et al. Cardiovascular outcomes trials in type 2 diabetes: where do we go from here? Reflections from a Diabetes Care editors' expert forum. Diabetes Care 41 (2018), 14–31.
125. DeFronzo, RA, Norton, L, Abdul-Ghani, M, Renal, metabolic and cardiovascular considerations of SGLT2 inhibition. Nat Rev Nephrol 13 (2017), 11–26.